**S2 Table: Overall estimated mean MAF of *CFH* rs121913059 (p.Arg1210Cys) and *CFH* rs35292876 across five geographical regions in the entire study and subdivided for individuals with and without advanced AMD**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **SNP** | **Continent** | **All individuals(n=39582)** | **Advanced1 (n=15527)** | **Non-Advanced2 (n=24055)** |
| *CFH* rs121913059 (p.Arg1210Cys) | East USA | 0.23 | 0.44 | 0.11 |
| West Europe | 0.17 | 0.32 | 0.06 |
| Britain | 0.08 | 0.21 | 0.03 |
| West USA | 0.13 | 0.25 | 0.05 |
| Australia | 0.08 | 0.23 | 0.01 |
| *CFH* rs35292876 | East USA | 1.53 | 2.14 | 1.19 |
| West Europe | 1.84 | 2.44 | 1.32 |
| Britain | 1.22 | 1.75 | 0.95 |
| West USA | 1.33 | 1.92 | 0.85 |
| Australia | 1.35 | 2.13 | 0.86 |

1 Advanced AMD defined as geographic atrophy and/or choroidal neovascularization in at least one eye. 2 Non-advanced AMD defined as pigmentary changes in the macula and/or more than five macular drusen with a diameter ≥63 μm or individuals without any reported signs of AMD